Tumor necrosis factor: The key to hepatitis B viral clearance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice.Rheumatology and therapy · 2022
   Review
2. [Progress in interferon: A treatment of Behcet syndrome].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020
   Article
3. Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment.BMC complementary medicine and therapies · 2020
   Article
4. CD4Frontiers in immunology · 2019
   Article
5. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.Frontiers in immunology · 2019
   Review
6. Liver-Mediated Adaptive Immune Tolerance.Frontiers in immunology · 2019
   Review

Corrections and comments

• Comment on
  Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model.2015

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as